Outputs

All 30 rebuilt CDISC pilot tables. Select one to view its PDF in-page.

The 30 safety and efficacy tables, rebuilt with tplyr2 (summaries) and clinify (styling). Select a table to open its page, where the DOCX is shown as an embedded PDF viewer with links to download the PDF / DOCX and view the program that builds it.

Table Population
14-1.01 — Summary of Populations All Subjects
14-1.02 — Summary of End of Study Data Intent-to-Treat
14-1.03 — Summary of Number of Subjects By Site All Subjects
14-2.01 — Summary of Demographic and Baseline Characteristics Intent-to-Treat
14-3.01 — Primary Endpoint Analysis: ADAS Cog (11) - Change from Baseline to Week 24 - LOCF Efficacy
14-3.02 — Primary Endpoint Analysis: CIBIC+ - Summary at Week 24 - LOCF Efficacy
14-3.03 — ADAS Cog (11) - Change from Baseline to Week 8 - LOCF Efficacy
14-3.04 — CIBIC+ - Summary at Week 8 - LOCF Efficacy
14-3.05 — ADAS Cog (11) - Change from Baseline to Week 16 - LOCF Efficacy
14-3.06 — CIBIC+ - Summary at Week 16 - LOCF Efficacy
14-3.07 — ADAS Cog (11) - Change from Baseline to Week 24 - Completers at Wk 24-Observed Cases-Windowed Completers
14-3.08 — ADAS Cog (11) - Change from Baseline to Week 24 in Male Subjects - LOCF Efficacy
14-3.09 — ADAS Cog (11) - Change from Baseline to Week 24 in Female Subjects - LOCF Efficacy
14-3.10 — ADAS Cog (11) - Mean and Mean Change from Baseline over Time Efficacy
14-3.11 — ADAS Cog (11) - Repeated Measures Analysis of Change from Baseline to Week 24 Efficacy
14-3.12 — Mean NPI-X Total Score from Week 4 through Week 24 - Windowed Efficacy
14-3.13 — CIBIC+ - Categorical Analysis - LOCF Efficacy
14-4.01 — Summary of Planned Exposure to Study Drug, as of End of Study Safety
14-5.01 — Incidence of Treatment Emergent Adverse Events by Treatment Group Safety
14-5.02 — Incidence of Treatment Emergent Serious Adverse Events by Treatment Group Safety
14-6.01 — Summary Statistics for Continuous Laboratory Values Safety
14-6.02 — Frequency of Normal and Abnormal (Beyond Normal Range) Laboratory Values During Treatment Safety
14-6.03 — Frequency of Normal and Abnormal (Clinically Significant Change from Previous Visit) Laboratory Values During Treatment Safety
14-6.04 — Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit Safety
14-6.05 — Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges Safety
14-6.06 — Shifts of Hy’s Law Values During Treatment Safety
14-7.01 — Summary of Vital Signs at Baseline and End of Treatment Safety
14-7.02 — Summary of Vital Signs Change from Baseline at End of Treatment Safety
14-7.03 — Summary of Weight Change from Baseline at End of Treatment Safety
14-7.04 — Summary of Concomitant Medications (Number of Subjects) Safety
No matching items